COLOPHON / EDITORIAL
About TB-500 Medicinal: what this console is, and what it is not.
An independent editorial digest of the peer-reviewed TB-500 and thymosin beta-4 literature. No clinic, no pharmacy, no product.
What this project is
TB-500 Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 — the synthetic Ac-LKKTETQ fragment of thymosin beta-4 — and on the full-length protein behind it. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site is built as a monitoring console because TB-500's literature is, at heart, a scattered-data problem: the same name sits on top of a body of evidence run almost entirely on a different, larger molecule. The console format — tagged findings, status chips, a citation register — is how we keep that distinction visible on every page rather than burying it in a caveat at the bottom.
What 'Medicinal' means here
The word medicinal in this domain is editorial framing, not a claim about services. It marks the register we read the literature in — the measured, instrument-panel posture of a research monitoring console that reports what the evidence and the regulatory record actually say: FDA-not-approved, WADA-prohibited, research and veterinary status, and 503A Category 2 under active review. It is not a clinic, a pharmacy, a counter, or a storefront, and it does not offer treatment, consultation, prescription, or supply.
We do not sell TB-500 and we do not tell anyone to obtain it. We read the studies, tag them to the molecule and species they used, cite them to source, and mark the gaps — most pointedly the absence of any completed controlled human trial of the fragment. Where the regulatory landscape is described, it is general information about that landscape, not medical or legal advice.
How we handle the evidence
Three rules govern the content. First, the molecule is always identified: a finding from the 7-mer fragment is tagged as such, and a finding from full-length thymosin beta-4 is tagged as such, so a reader never silently inherits a protein result as a fragment result. Second, every quantitative claim resolves to a primary source in the citation register — a peer-reviewed study or an authoritative FDA page. Third, established results are presented plainly and gaps are labeled plainly; we do not inflate animal mechanism into human benefit, and we do not soften the tumor and angiogenesis safety signal.
The established findings here are real and reproducible in animals. The human efficacy of the TB-500 fragment is unproven. Both statements are true, and this project's job is to hold them in view at the same time.